Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Acquires Swiss Biotech To Expand Neurology Pipeline
Executive Summary
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
You may also be interested in...
Merck KGaA Plumps For Reinvention To Refuel R&D
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
Merck KGaA Health Care Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
Merck KGaA Healthcare Head Happy With Old And New Mix
The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.